BTA
Click for more information
0.00% 57.0¢ biota holdings limited

resistance study favours shift from tamiflu, page-2

  1. PortableAlpha
    3,045 Posts.
    clock Created with Sketch.
    30/01/10
    21:46
    Post #: 6266270
    We just don't see it but GSK are pushing hard to sell Relenza to stockpilers, and all the evidence on tamiflu resistance will assist their cause. This coming quarterly will homefully confirm what many investors have been anticipating, a large global shift towards Relenza.
    BTA Price at posting: $2.00 Sentiment: Buy Disclosure: Held
    Likes Created with Sketch.  Upvote
    lightbulb Created with Sketch.  Great analysis
    Stroke 3 Created with Sketch. Comments Created with Sketch. Reply

  2. Top Stories

 

Featured News

SUN ANZ deal to buy Suncorp to go ahead following approval from Treasurer
right-arrow Created with Sketch.
3DP Pointerra wins US$1.63M from US Dept of Energy to model climate change scenarios
right-arrow Created with Sketch.
PDN Paladin flags up to 4.5Mlbs of uranium production in FY25 guidance
right-arrow Created with Sketch.
LYC Lynas eyes first dysprosium, terbium HREE production in CY25
right-arrow Created with Sketch.
PH2 Pure Hydrogen to supply hydrogen-fuelled garbage truck to City of Newcastle
right-arrow Created with Sketch.
NIM Nimy extends sulphide targets at Mons with new anomalies identified
right-arrow Created with Sketch.
watchlist Created with Sketch. Add BTA (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.